Lumida
/AYTU
⌘K
AYTU

AYTU

AYTU
$1.99USD↓-2.93%-0.06 today

MARKET CAP

21.4M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$2
$3

The case for & against

Bull & Bear analysis

Bullish

Aytu BioPharma (NASDAQ: AYTU) is a clinical-stage biopharmaceutical company primarily focused on developing and commercializing innovative therapies for central nervous system disorders, particularly in the fields of mental health. With the launch of its new drug Exua – a selective serotonin 5-HT1A receptor agonist indicated for major depressive disorder (MDD) – Aytu is positioning itself as a key player in addressing significant unmet needs within a large and growing market, particularly as mental health awareness continues to rise.

Bull says

  • ↑Exua revenue hit $2.4M with over 1,300 prescriptions in Q3.
  • ↑Prescription growth accelerated from 200 in January to 700 in March.
  • ↑61% gross margin maintained with $1–2M planned promotional spend.
  • ↑First FDA-approved 5-HT1A agonist for MDD addresses common side effects.
  • ↑Analyst revisions trending higher reflect optimistic earnings outlook.
  • ↑Low leverage and strong book-to-price factor support potential upside.

Bear says

  • ↓ADHD portfolio revenue fell 41% YoY to $9.1M.
  • ↓Q3 net revenue declined 33% YoY to $12.4M.
  • ↓Net loss grew to $5.6M amid $11.7M in operating expenses.
  • ↓Rising launch costs risk compressing margins below 61%.
  • ↓Competing generics like Teva’s Adzenis threaten Exua uptake.
  • ↓Negative earnings yield and momentum factors signal caution.

Earnings Call · Q2 2026 · Mgmt. Guidance

Updated 04-09-2026neutral

Transcript signals

Bull points

  • I'm excited to be speaking with you on what is truly a momentous time for A2 as we just commercially launched Exua, the first and only 5-HT1A agonist approved by the FDA for the treatment of MDD, representing a truly novel way to treat MDD.
  • Exua represents a fundamentally different, more targeted approach, specifically designed to engage the 5-HT1A receptor, which is thought to be central to antidepressant efficacy.
  • which does not carry a warning for sexual dysfunction and demonstrated a neutral sexual profile in clinical studies with no sexual-related adverse event rates exceeding placebo and showed no clinically meaningful weight gain compared to placebo across pivotal trials.

Bear points

  • Net revenue for the quarter was $15.2 million compared to $16.2 million for the prior year. The ADHD portfolio net revenue was $13.2 million compared to $13.8 million in the prior year period. For the quarter, we reported a net loss of $10.6 million, or $1.05 net loss per share basic compared to net income of $0.8 million, or $0.13 net income per share basic in the prior year period.
  • The fiscal 2026 second quarter results were impacted by derivative warrant liability loss of $8.2 million, while the year-ago period had a derivative warrant liability gain of $3 million.
  • adjusted EBITDA was a negative 0.8 million for the second quarter of fiscal 2026, compared to a positive 1.3 million in the year-ago period.
Read full transcript analysis ›